Efgartigimod alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Efgartigimod alfa
DrugBank Accession Number
DB15270
Background

Efgartigimod alfa is under investigation in clinical trial NCT03669588 (An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness).

Type
Biotech
Groups
Investigational
Synonyms
  • Efgartigimod alfa
External IDs
  • ARGX-113

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
961YV2O515
CAS number
1821402-21-4

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentGeneralized Myasthenia Gravis1
3CompletedTreatmentGeneralized Myasthenia Gravis1
3Not Yet RecruitingTreatmentPrimary Immune Thrombocytopenia1
3RecruitingTreatmentPrimary Immune Thrombocytopenia3
3WithdrawnTreatmentPrimary Immune Thrombocytopenia (ITP)1
2CompletedTreatmentMyasthenia Gravis1
2CompletedTreatmentPemphigus Foliaceus / Pemphigus Vulgaris (PV)1
2CompletedTreatmentPrimary Immune Thrombocytopenia1
2RecruitingTreatmentChronic Inflammatory Demyelinating Polyneuropathy (CIDP)1
1CompletedBasic ScienceBioavailability Study1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 15:06 / Updated on February 21, 2021 18:55